Literature DB >> 15022148

Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder.

Paolo Meoni1, David Hackett, Malcolm Lader.   

Abstract

We evaluated the relative efficacy of venlafaxine XR on the psychic versus somatic symptoms of anxiety in patients with generalized anxiety disorder as determined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Data were pooled and analyzed from 1,841 patients with generalized anxiety disorder who participated in five short-term (8-week) double-blind, multicenter, placebo-controlled studies, two of which had long-term (6-month) extensions. Somatic and psychic anxieties were studied using the Hamilton rating scale for anxiety (HAM-A) factor scores. We examined response rates (> or =50% improvement over baseline severity score) in the overall population and in patients with mainly somatic symptomatology at baseline (somatizers). Venlafaxine XR significantly reduced factor scores for both psychic and somatic HAM-A factors compared with placebo, from the first and second weeks of treatment, respectively. Patients treated with venlafaxine XR had significantly higher rates of response than patients receiving placebo on the psychic (58% vs. 38%, P<.001 at week 8; 66% vs. 35% at week 24, P<.001) and somatic (56% vs. 43%, P<.001 at week 8; 67% vs. 47% at week 24, P<.001) factors of the HAM-A. There was a TreatmentxFactor interaction (P<.027) in response rates: Patients treated with venlafaxine showed similar somatic and psychic anxiety response rates, whereas placebo-treated patients showed higher somatic compared with psychic response rates. Somatizers showed similar rates of response to the total population for the somatic factor of the HAM-A in either treatment group. Patients with generalized anxiety disorder treated with venlafaxine XR showed similar absolute rates of response on somatic and psychic symptoms, but relative to patients treated with placebo, more improvement in psychic than somatic symptoms. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15022148     DOI: 10.1002/da.10141

Source DB:  PubMed          Journal:  Depress Anxiety        ISSN: 1091-4269            Impact factor:   6.505


  8 in total

1.  The effects of acute treatment with escitalopram on the different stages of contextual fear conditioning are reversed by atomoxetine.

Authors:  Liliana P Montezinho; Silke Miller; Niels Plath; Nanna Hovelsø Jensen; Jens-Jakob Karlsson; Louise Witten; Arne Mørk
Journal:  Psychopharmacology (Berl)       Date:  2010-07-30       Impact factor: 4.530

Review 2.  Redefining affective disorders: relevance for drug development.

Authors:  Steven D Targum; Mark H Pollack; Maurizio Fava
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

3.  Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone.

Authors:  Arif Khan; Suresh Durgam; Xiongwen Tang; Adam Ruth; Maju Mathews; Carl P Gommoll
Journal:  Prim Care Companion CNS Disord       Date:  2016-04-28

4.  Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis.

Authors:  Xinyuan Li; Lijun Zhu; Yingying Su; Shaokuan Fang
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

5.  Efficacy of Agomelatine 25-50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies.

Authors:  Dan J Stein; Jon-Paul Khoo; Françoise Picarel-Blanchot; Valérie Olivier; Michael Van Ameringen
Journal:  Adv Ther       Date:  2021-02-04       Impact factor: 3.845

6.  Relative Safety and Efficacy of Two Doses of Tandospirone Citrate for Generalized Anxiety Disorder: A Multicenter Randomized Controlled Trial.

Authors:  Qingwei Li; Haiyin Zhang; Guozhen Lin; Shenxun Shi; Yingli Zhang; Jianlin Ji; Lipeng Yang; Jun Yao; Wenyuan Wu
Journal:  Neuropsychiatr Dis Treat       Date:  2022-08-08       Impact factor: 2.989

Review 7.  The noradrenergic paradox: implications in the management of depression and anxiety.

Authors:  Alonso Montoya; Robert Bruins; Martin A Katzman; Pierre Blier
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-01       Impact factor: 2.570

8.  Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis.

Authors:  Xinyuan Li; Lijun Zhu; Chunkui Zhou; Jing Liu; Heqian Du; Chenglin Wang; Shaokuan Fang
Journal:  PLoS One       Date:  2018-03-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.